English Korean Chinese
ホーム > 市場調査レポート > 医薬品 > 世界の治療用ボツリヌス毒素市場：2009年
カテゴリ
医薬品 (4964)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (181)
感染症 (353)
規制環境 (132)
後発医薬品 (135)
骨疾患 (37)
処方薬 (158)
神経疾患 (174)
精神疾患 (89)
製薬企業関連 (531)
創薬 (1524)
糖尿病 (193)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

世界の治療用ボツリヌス毒素市場：2009年

Global Markets for Therapeutic Botulinum Toxin 2009

発行 Millennium Research Group
出版日 2008年07月 商品コード 76548
ページ情報 英文  
価格
US$ 4,197 換算 ¥ 337,732 (税抜) Web Access and PDF Download (Single user license)
US$ 6,300 換算 ¥ 506,961 (税抜) Web Access and PDF Download (Corporate use license)


原文目次

Abstract

The global therapeutic botulinum toxin (BTX) market, including the US, Europe (France, Germany, Italy, Spain, and the UK), and Japan, exceeded $600 million in 2008

Through 2013, growth will be fueled by the approval of new treatment indications of BTX, which will significantly expand procedure volumes and bolster unit demand

Table of Contents

TABLE OF CONTENTS

LIST OF EXHIBITS

EXECUTIVE SUMMARY

METHODOLOGY

1.0 GLOBAL THERAPEUTIC BOTULINUM TOXIN MARKET

  • 1.1 Market Overview
  • 1.2 Market Analysis
    • 1.2.1 Product Background
    • 1.2.2 Procedure Overview
    • 1.2.2.1 US Procedures
    • Cervical Dystonia Procedures
    • Blepharospasm Procedures
    • Strabismus Procedures
    • Severe Primary Axillary Hyperhidrosis
    • 1.2.2.2 European Procedures
    • 1.2.2.3 Japanese Procedures
    • 1.2.2.4 Emerging Procedures
    • 1.2.3 Market Forecast
    • 1.2.3.1 US Therapeutic Botulinum Toxin Market
    • 1.2.3.2 European Therapeutic Botulinum Toxin Market
    • 1.2.3.3 Japanese Therapeutic Botulinum Toxin Market
    • 1.2.4 Market Drivers and Limiters
    • 1.2.4.1 Market Drivers
    • 1.2.4.2 Market Limiters
  • 1.3 Competitive Analysis
    • 1.3.1 Leading Competitors
    • 1.3.2 Emerging Competitors

2.0 US THERAPEUTIC BOTULINUM TOXIN MARKET

  • 2.1 Market Overview
  • 2.2 Market Analysis
    • 2.2.1 Market Forecast
    • 2.2.2 Market Drivers and Limiters
    • 2.2.2.1 Market Drivers
    • 2.2.2.2 Market Limiters
  • 2.3 Competitive Analysis
    • 2.3.1 Leading Competitors
    • 2.3.2 Emerging Competitors

3.0 EUROPEAN THERAPEUTIC BOTULINUM TOXIN MARKET

  • 3.1 Market Overview
  • 3.2 Market Analysis
    • 3.2.1 Market Forecast
    • 3.2.2 Market Drivers and Limiters
    • 3.2.2.1 Market Drivers
    • 3.2.2.2 Market Limiters
  • 3.3 Competitive Analysis
    • 3.3.1 Leading Competitors
    • 3.3.2 Emerging Competitors

4.0 JAPANESE THERAPEUTIC BOTULINUM TOXIN MARKET

  • 4.1 Market Overview
  • 4.2 Market Analysis
    • 4.2.1 Market Forecast
    • 4.2.2 Market Drivers and Limiters
    • 4.2.2.1 Market Drivers
    • 4.2.2.2 Market Limiters
  • 4.3 Competitive Analysis
    • 4.3.1 Leading Competitors
    • 4.3.2 Emerging Competitors

APPENDIX A: MRG ACRONYMS AND INITIALISMS

APPENDIX B: SUPPLEMENTAL EXHIBITS

List of Exhibits

  • EXECUTIVE SUMMARY
  • Exhibit 1: Therapeutic BTX Market, Global (US$), 2007 - 2013
  • Exhibit 2: Therapeutic BTX Market, by Indication, US, as a % of Total, 2008 and 2013
  • Exhibit 3: Therapeutic BTX Market Units, Europe, 2007 - 2013
  • Exhibit 4: Therapeutic BTX Market, Japan (US$), 2007 - 2013
  • Exhibit 5: Leading Competitors in the Therapeutic BTX Market, Global, 2008

METHODOLOGY

  • Exhibit 6: Currency Exchange Rates, 2008

CHAPTER 1: GLOBAL THERAPEUTIC BOTULINUM TOXIN MARKET

  • Exhibit 7: Therapeutic BTX Market, by Country, Global (US$), 2007 - 2013 (Graphical Format)
  • Exhibit 8: Therapeutic BTX Product Overview, Global, 2008
  • Exhibit 9: Therapeutic BTX Procedures, by Country, Global, 2007 - 2013
  • Exhibit 10: Therapeutic BTX Procedures, by Procedure Type, US, 2007 - 2013
  • Exhibit 11: Therapeutic BTX Procedures, by Country, Europe, 2007 - 2013
  • Exhibit 12: Therapeutic BTX Procedures, Japan, 2007 - 2013
  • Exhibit 13: Therapeutic BTX Market, by Country, Global (US$), 2007 - 2013 (Tabular Format)
  • Exhibit 14: Therapeutic BTX Market, by Country, Global (€ , £, and ¥), 2007 - 2013 Exhibit 15: Drivers and Limiters of the Therapeutic BTX Market, Global
  • Exhibit 16: Leading Competitors in the Therapeutic BTX Market, by Country, as % of Total, Global, 2008

CHAPTER 2: US THERAPEUTIC BOTULINUM TOXIN MARKET

  • Exhibit 17: Therapeutic BTX Market, US (US$), 2007 - 2013 (Graphical Format)
  • Exhibit 18: Therapeutic BTX Market, US (US$), 2007 - 2013 (Tabular Format)
  • Exhibit 19: Therapeutic BTX Market Growth, US, 2008 - 2013
  • Exhibit 20: Drivers and Limiters of the Therapeutic BTX Market, US
  • Exhibit 21: Leading Competitors in the Therapeutic BTX Market, as a % of Total, US, 2008

CHAPTER 3: EUROPEAN THERAPEUTIC BOTULINUM TOXIN MARKET

  • Exhibit 22: Therapeutic BTX Market, by Country, Europe (US$), 2007 - 2013 (Graphical Format)
  • Exhibit 23: Therapeutic BTX Market, by Country, Europe (US$), 2007 - 2013 (Tabular Format)
  • Exhibit 24: Therapeutic BTX Market, by Country, Europe (€ and £), 2007 - 2013
  • Exhibit 25: Therapeutic BTX Market Growth, by Country, Europe, 2008 - 2013
  • Exhibit 26: Drivers and Limiters of the Therapeutic BTX Market, Europe
  • Exhibit 27: Leading Competitors in the Therapeutic BTX Market, by Country, as a % of Total, Europe, 2008

CHAPTER 4: JAPANESE THERAPEUTIC BOTULINUM TOXIN MARKET

  • Exhibit 28: Therapeutic BTX Market, Japan (US$), 2007 - 2013
  • Exhibit 29: Therapeutic BTX Market, Japan (US$ and ¥), 2007 - 2013
  • Exhibit 30: Therapeutic BTX Market Growth, Japan, 2008 - 2013
  • Exhibit 31: Drivers and Limiters of the Therapeutic BTX Market, Japan
  • Exhibit 32: Leading Competitors in the Therapeutic BTX Market, as a % of Total, Japan, 2008

APPENDIX B: SUPPLEMENTAL EXHIBITS

  • Exhibit 33: Therapeutic BTX Market, Global (US$), 2007 - 2013 (Detailed Format)
  • Exhibit 34: Therapeutic BTX Market, by Indication, US, as a % of Total, 2008 and 2013 (Detailed Format)
  • Exhibit 35: Therapeutic BTX Market Units, Europe, 2007 - 2013 (Detailed Format)
  • Exhibit 36: Therapeutic BTX Market, Japan (US$), 2007 - 2013 (Detailed Format)
Back to Top